The Latest Cardiac and Vascular News
OPTIMIZE Pivotal Study 1 Year Outcomes Announced at TCT Connect NEW PROVIDENCE, N.J.–(BUSINESS WIRE)–The Svelte® Drug-Eluting Stent (DES) achieved 1.5% clinically-driven Target Lesion Revascularization (TLR) at 1 year, the lowest ever reported in an Investigational Device Exemption (IDE) clinical study. Primary […]
NEW PROVIDENCE, N.J.–(BUSINESS WIRE)– The Christ Hospital, Lindner Research Center in Cincinnati, Ohio, enrolled the first patient in Svelte Medical System’s OPTIMIZE clinical study, designed to further assess the safety and effectiveness of the Svelte Drug-Eluting Stent (DES) Integrated Delivery […]
